Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.
Source: NLP:nirogacestat
3 interactions on record
Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.
Source: NLP:nirogacestat
Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutinib concentrations.
Source: NLP:ibrutinib
Seville oranges are strong CYP3A inhibitors. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.
Source: NLP:rilzabrutinib